News | October 08, 2008

Endosense Launches Safety Study of TactiCath System for Atrial Arrhythmias

October 9, 2008 – Endosense this week launched the TOCCATA (TOuCh for CATheter Ablation) clinical study to evaluate the safety of the TactiCath system for the treatment of atrial arrhythmias, with enrollment gaining momentum.

TOCCATA is a 70 patient European multi-center safety study. Constructed to gain the CE mark for the treatment of atrial arrhythmias, secondary endpoints were designed to evaluate the value of force-sensing in successfully impacting outcomes of the ablation procedure.

The start of this clinical trial marks the first use of the TactiCath force-sensing catheter in patients. Ten patients have been treated so far by different investigators including Endosense European Scientific Advisors Professor Karl-Heinz Kuck, M.D., at St. Georg Hospital in Hamburg, Germany, Professor Dipen Shah, M.D., at the University Hospital of Geneva, Switzerland and Professor Nadir Saoudi, M.D., at the Princess Grace Hospital, Monaco. The patients treated to date have had different arrhythmia pathologies, including atrial fibrillation.

“The first TOCCATA patients had their arrhythmia successfully treated at acute follow-up. The physicians’ experiences have shown the tremendous potential of force-sensing to the clinical practice, and we’re hopeful that the results will reinforce our initial findings,” said Pr. Kuck, the principal investigator of TOCCATA.

TactiCath is the first force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. It has the potential to impact safety and performance of the catheter ablation treatment of cardiac rhythm disorders, including atrial fibrillation (AF). AF is the most common cardiac rhythm disorder today, affecting more than 6 million people worldwide. Most AF patients are currently treated with ineffective and side effect-causing pharmaceutical drugs, with the primary alternative invasive ablation surgery. Endosense is focused on providing this sizeable patient population with a minimally invasive treatment option that is both safe and effective.

For more information: www.endosense.com

Related Content

FDA Approves Biosense Webster's Tag-Index Guided Ablation Software
Technology | Ablation Systems | October 09, 2018
Biosense Webster Inc. recently received approval from the U.S. Food and Drug Administration (FDA) for its Visitag...
Medtronic Cryoballoon Improves Quality of Life, Reduces Systems of Persistent Atrial Fibrillation
News | Ablation Systems | August 28, 2018
Medtronic plc announced new findings from the CRYO4PERSISTENT AF clinical trial demonstrating improved quality of life...
Thermedical Announces FDA IDE Approval for Clinical Study of Durablate Catheter
News | Ablation Systems | August 02, 2018
Thermedical announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device...
Boston Scientific to Acquire Cryterion Medical Inc.
News | Ablation Systems | July 13, 2018
Boston Scientific Corp. recently announced a definitive agreement to acquire Cryterion Medical Inc., a privately-held...
Treating AFib With Ablation Reduces Mortality and Stroke
News | Ablation Systems | July 05, 2018
Using catheter-based ablation instead of medications alone reduces the risks of death and stroke in patients with the...
LuxCath Showcases OmniView Light-Guided Ablation Catheter at HRS 2018
News | Ablation Systems | May 22, 2018
LuxCath LLC showcased the next generation of its proprietary OmniView light-guided catheter ablation system at the 2018...
The Kardium Globe combined mapping and ablation catheter. The device has a distal multi-electrode array consisting of 16 ribs with 122 gold-plated electrodes. Ablation can be done with up to 24 electrodes simultaneously.  #HRS2018

The Kardium Globe combined mapping and ablation catheter. The device has a distal multi-electrode array consisting of 16 ribs with 122 gold-plated electrodes. Ablation can be done with up to 24 electrodes simultaneously. 

News | Ablation Systems | May 21, 2018
May 21, 2018 — Complete pulmonary vein isolation (PVI) was achieved in more than 99 percent of patients in a first-in
CardioFocus Announces Successful Live Case Featuring HeartLight X3 System
News | Ablation Systems | May 17, 2018
Medical device manufacturer CardioFocus Inc. announced a successful live case featuring its HeartLight X3 System during...
Imricor MRI-Guided Cardiac Ablation Study Results to Be Presented at HRS 2018
News | Ablation Systems | May 10, 2018
Results from the clinical study to evaluate Imricor’s Vision-MR Ablation Catheter for the treatment of atrial flutter...
Biosense Webster Launches Carto Vizigo Bi-Directional Guidance Sheath
Technology | Ablation Systems | May 08, 2018
Biosense Webster Inc. announced its Carto Vizigo Bi-directional Guiding Sheath is now available in the United States....
Overlay Init